269 related articles for article (PubMed ID: 12453919)
1. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
[TBL] [Abstract][Full Text] [Related]
2. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
3. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
[TBL] [Abstract][Full Text] [Related]
4. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
Agarwal AK; Garg A
J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
[TBL] [Abstract][Full Text] [Related]
5. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy.
Vigouroux C; Magré J; Vantyghem MC; Bourut C; Lascols O; Shackleton S; Lloyd DJ; Guerci B; Padova G; Valensi P; Grimaldi A; Piquemal R; Touraine P; Trembath RC; Capeau J
Diabetes; 2000 Nov; 49(11):1958-62. PubMed ID: 11078466
[TBL] [Abstract][Full Text] [Related]
6. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
8. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
9. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy.
Cao H; Hegele RA
Hum Mol Genet; 2000 Jan; 9(1):109-12. PubMed ID: 10587585
[TBL] [Abstract][Full Text] [Related]
10. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy.
Hegele RA; Cao H; Anderson CM; Hramiak IM
J Clin Endocrinol Metab; 2000 Sep; 85(9):3431-5. PubMed ID: 10999845
[TBL] [Abstract][Full Text] [Related]
12. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C.
Speckman RA; Garg A; Du F; Bennett L; Veile R; Arioglu E; Taylor SI; Lovett M; Bowcock AM
Am J Hum Genet; 2000 Apr; 66(4):1192-8. PubMed ID: 10739751
[TBL] [Abstract][Full Text] [Related]
13. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
[TBL] [Abstract][Full Text] [Related]
15. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations.
Mory PB; Crispim F; Freire MB; Salles JE; Valério CM; Godoy-Matos AF; Dib SA; Moisés RS
Eur J Endocrinol; 2012 Sep; 167(3):423-31. PubMed ID: 22700598
[TBL] [Abstract][Full Text] [Related]
17. Atypical generalized lipoatrophy and severe insulin resistance due to a heterozygous LMNA p.T10I mutation.
Mory PB; Crispim F; Kasamatsu T; Gabbay MA; Dib SA; Moisés RS
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1252-6. PubMed ID: 19169477
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
[TBL] [Abstract][Full Text] [Related]
19. LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration.
Hegele RA; Cao H; Huff MW; Anderson CM
J Clin Endocrinol Metab; 2000 Sep; 85(9):3089-93. PubMed ID: 10999791
[TBL] [Abstract][Full Text] [Related]
20. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
